# US 2023/0406860 A1 · Heterocyclic spiro compounds and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406860 A1
- Document ID: US20230406860A1
- Status: Published application
- Kind: A1
- Application number: 18/033,439
- Filed: 2021-10-26
- Published: 2023-12-21
- Earliest claimed: 2020-10-27
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: BRIAN ALAN LANMAN; ABHISEK BANERJEE; MARGARET CHU-MOYER; DONGCHENG DAI; MATTHEW R. KALLER; PATRICIA LOPEZ; VU VAN MA; FRANCESCO MANONI; JOSE M. MEDINA; ALEXANDER J. PICKRELL; NURIA A. TAMAYO; KAI ZHU
- Web page: https://patentgrep.com/patent/US20230406860A1

## CPC

- C07D 487/10: Spiro-condensed systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 491/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides compounds of Formula (I) having activity as inhibitors of G12C mutant KRAS protein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic and colorectal cancers.

## Claims

### Claim 1

A compound of Formula I
or a pharmaceutically acceptable salt thereof, wherein
R1 at each occurrence independently is H, C1-4alkoxy, —(CH2)—C1-4dialkylamino, aziridin-1-yl-methyl, azetidin-1-yl-methyl, pyrrolidine-1-yl-methyl, piperidin-1-yl-methyl, or morpholin-1-yl-methyl;
R2 is H, halogen, —CN, C1-4alkyl, C1-4haloalkyl, —CH2CN, —CH2OH, C1-4alkoxy, or C1-4haloalkoxy;
wherein, optionally, one R1 and R2 together with the carbon atoms to which they are attached form a
group;
R3 at each occurrence independently is H, halogen, CN, OH, —CH2OH, C1-4alkyl, C1-4haloalkyl, —CH2CN, or C1-4alkoxy, wherein two substituents R3 attached to the same carbon atom optionally form together with said carbon atom a C3-6cycloalkyl or a carbonyl group;
A at each occurrence independently is CR3R3 or absent;
R4 is Z1—CH(Z2—R5)—CH2—R6;
Z1 is O, NH, N(C1-4alkyl), or CH2;
Z2 is absent or CH2;
R5 is C1-4alkyl, C1-4haloalkyl, C3-6cycloalkyl, C3-6heterocycloalkyl, phenyl, or 5 to 6 membered heteroaryl,
wherein the phenyl is optionally substituted with 1 to 3 substituents selected from halogen, —CN, C1-3alkyl, C1-3haloalkyl, C1-3alkoxy, and C1-3haloalkoxy,
wherein the heteroaryl is optionally substituted with 1-3 substituents selected from —CN, C1-4alkyl, C1-4haloalkyl C1-4alkoxy, and C1-4haloalkoxy;
R6 is —CO(NR7R7), phenyl, 5,5-dimethyl-3,5-dihydro-4H-imidazol-4-one-2-yl, or 5 to 6 membered heteroaryl, wherein the heteroaryl is optionally substituted with 1-3 substituents selected from —CN, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, and C1-4haloalkoxy;
R7 at each occurrence independently is H or C1-4alkyl;
X1 is CR8 or N;
X2 is CH, or N;
X3 is C or N;
X4 is C or N;
R8 is H, halogen, CN, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, C1-4haloalkoxy, C3-5cycloalkyl, or C3-5cyclohaloalkyl;
B together with the atoms to which it is attached forms a 4 to 7 membered fully saturated, fully unsaturated, or partially unsaturated carbocyclic or heterocyclic ring system,
wherein the heterocyclic ring system comprises 1 to 5 heteroatoms selected from N, O, and S,
wherein the ring system is optionally substituted with 1 to 5 substituents R9;
R9 at each occurrence independently is halogen, OH, —CN, —NH2, C(═O)C1-6alkyl, C1-6alkyl, CL-6haloalkyl, C1-4alkoxy, C1-4haloalkoxy, C3-5cycloalkyl, C3-5cyclohaloalkyl, phenyl, or 5 to 6 membered heteroaryl,
wherein the C1-6alkyl is optionally substituted with —CO(C1-4alkylamino) or —CO(C1-4dialkylamino),
wherein the phenyl is optionally substituted with 1 to 3 independently selected halogens,
wherein the heteroaryl is optionally substituted with 1 to 3 substituents selected from halogen, C1-4alkyl, and C1-4haloalkyl,
wherein two substituents R9 together optionally form a —(CH2)n— group creating a ring together with the ring atom or ring atoms to which the two substituents R9 are attached, wherein the —(CH2)n— group optionally has one —CH2— group substituted with one heteroatom selected from N, O and S; and
n is 1, 2, 3, or 4.

### Claim 2 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein
R3 is not —CN; or
Z2 is absent and R5 is 2-cyanophenyl; or
R5 is not pyrazol-3-yl, 2-methyl; or
B is not

### Claim 3 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is not
(3R)-3-(3-cyanophenyl)-N-methyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)propanamide;
(3S)-3-((2-((7S)-7-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)-N,5-dimethylhexanamide;
1-(6-(4-(((2S)-4-methyl-1-(1H-pyrazol-3-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
(3S)-3-((2-(8-cyano-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-quinazolinyl)amino)-N,5-dimethylhexanamide;
(3S)-3-(2-cyanophenyl)-N-methyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)propanamide;
(3R)-3-(2-cyanophenyl)-N-methyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)propanamide;
(3S)—N,5-dimethyl-3-((8-methyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-yl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((7-(2-propanyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexanamide; or
(3S)—N,5-dimethyl-3-((7-methyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7H-purin-6-yl)amino)hexanamide.

### Claim 4 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has an IC50 of less than 10 μM in the 2 h coupled exchange assay or the 20 h coupled exchange assay.

### Claim 5 (depends on 1, 2, 3, 4)

The compound according to any one of claims 1-4 or a pharmaceutically acceptable salt thereof, wherein
each R1 is H.

### Claim 6 (depends on 1, 2, 3, 4)

The compound according to any one of claims 1-4 or a pharmaceutically acceptable salt thereof, wherein
one R1 and R2 together with the carbon atoms to which they are attached form a
group.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The compound according to any one of claims 1-5 or a pharmaceutically acceptable salt thereof, wherein
R2 is H or C1-4haloalkyl.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The compound according to any one of claims 1-5 or a pharmaceutically acceptable salt thereof, wherein
R2 is H or CF3.

### Claim 9 (depends on 1, 2, 3, 4, 5)

The compound according to any one of claims 1-5 or a pharmaceutically acceptable salt thereof, wherein
R2 is H.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound according to any one of claims 1-9 or a pharmaceutically acceptable salt thereof, wherein
R3 is H or halogen.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound according to any one of claims 1-9 or a pharmaceutically acceptable salt thereof, wherein
R3 is H or F.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound according to any one of claims 1-9 or a pharmaceutically acceptable salt thereof, wherein
R3 is H.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound according to any one of claims 1-12 or a pharmaceutically acceptable salt thereof, wherein
one A is absent and the other A is CR3R3.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound according to any one of claims 1-12 or a pharmaceutically acceptable salt thereof, wherein
both A are absent.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound according to any one of claims 1-12 or a pharmaceutically acceptable salt thereof, wherein

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound according to any one of claims 1-12 or a pharmaceutically acceptable salt thereof, wherein

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound according to any one of claims 1-12 or a pharmaceutically acceptable salt thereof, wherein

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound according to any one of claims 1-17 or a pharmaceutically acceptable salt thereof, wherein
Z1 is NH.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound according to any one of claims 1-18 or a pharmaceutically acceptable salt thereof, wherein
Z2 is CH2.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound according to any one of claims 1-18 or a pharmaceutically acceptable salt thereof, wherein
Z2 is absent.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The compound according to any one of claims 1-20 or a pharmaceutically acceptable salt thereof, wherein
R5 is C1-4alkyl or phenyl, wherein the phenyl is optionally substituted with —CN.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The compound according to any one of claims 1-20 or a pharmaceutically acceptable salt thereof, wherein
R5 is —CH(CH3)2, phenyl, or 3-cyanophenyl.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The compound according to any one of claims 1-20 or a pharmaceutically acceptable salt thereof, wherein
R5 is —CH(CH3)2.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The compound according to any one of claims 1-23 or a pharmaceutically acceptable salt thereof, wherein
R6 is —CO(NR7R7), 5,5-dimethyl-3,5-dihydro-4H-imidazol-4-one-2-yl, or 5 membered heteroaryl, wherein the heteroaryl is optionally substituted with 1-3 C1-4alkyl substituents; and
R7 at each occurrence independently is H or C1-4alkyl.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The compound according to any one of claims 1-23 or a pharmaceutically acceptable salt thereof, wherein
R6 is —CO(NHR7) or 5 membered heteroaryl, wherein the heteroaryl is optionally substituted with one C1-4alkyl substituent; and
R7 is C1-4alkyl.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The compound according to any one of claims 1-23 or a pharmaceutically acceptable salt thereof, wherein
R6 is —CO(NHCH3), 5,5-dimethyl-3,5-dihydro-4H-imidazol-4-one-2-yl, or 5 membered heteroaryl, wherein the heteroaryl is pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, 1,2-oxazole, 1,3-oxazole, 1,3,4-oxadiazole, 1,2,4-oxadiazole, 1,3-thiazole, or 1,3,4-thiadiazol, and the heteroaryl is optionally substituted with one C1-4alkyl substituent.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The compound according to any one of claims 1-23 or a pharmaceutically acceptable salt thereof, wherein
R6 is —CO(NHCH3), or 5 membered heteroaryl, wherein the heteroaryl is, imidazole, 1,2-oxazole, 1,3,4-oxadiazole, 1,3,4-thiadiazol, or 1,2,3-triazole, and the heteroaryl is optionally substituted with one methyl group.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound according to any one of claims 1-17 or a pharmaceutically acceptable salt thereof, wherein

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound according to any one of claims 1-17 or a pharmaceutically acceptable salt thereof, wherein
R4 is

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound according to any one of claims 1-29 or a pharmaceutically acceptable salt thereof, wherein
X1 is CR8.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound according to any one of claims 1-29 or a pharmaceutically acceptable salt thereof, wherein
X1 is N.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound according to any one of claims 1-31 or a pharmaceutically acceptable salt thereof, wherein
X2 is CH.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound according to any one of claims 1-31 or a pharmaceutically acceptable salt thereof, wherein
X2 is N.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The compound according to any one of claims 1-33 or a pharmaceutically acceptable salt thereof, wherein
X3 is C.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The compound according to any one of claims 1-33 or a pharmaceutically acceptable salt thereof, wherein
X3 is N.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The compound according to any one of claims 1-35 or a pharmaceutically acceptable salt thereof, wherein
X4 is C.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The compound according to any one of claims 1-35 or a pharmaceutically acceptable salt thereof, wherein
X4 is N.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound according to any one of claims 1-29 or a pharmaceutically acceptable salt thereof, wherein
X1 is N, X2 is N, X3 is C, and X4 is C; or
X1 is N, X2 is CH, X3 is C, and X4 is C; or
X1 is N, X2 is N, X3 is N, and X4 is C; or
X1 is N, X2 is CH, X3 is C, and X4 is N.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound according to any one of claims 1-29 or a pharmaceutically acceptable salt thereof, wherein
X1 is N, X2 is N, X3 is C, and X4 is C; or
X1 is N, X2 is CH, X3 is C, and X4 is C; or

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound according to any one of claims 1-29 or a pharmaceutically acceptable salt thereof, wherein
X1 is N, X2 is N, X3 is C, and X4 is C.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36)

The compound according to any one of claims 1-34, 36, and 38-40 or a pharmaceutically acceptable salt thereof, wherein
B together with the atoms to which it is attached forms a ring system selected from
wherein the ring system is optionally substituted with 1 to 5 substituents R9.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36)

The compound according to any one of claims 1-34, 36, and 38-40 or a pharmaceutically acceptable salt thereof, wherein
B together with the atoms to which it is attached forms a ring system selected from
wherein the ring system is optionally substituted with 1 to 5 substituents R9.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36)

The compound according to any one of claims 1-34, 36, and 38-40 or a pharmaceutically acceptable salt thereof, wherein
B together with the atoms to which it is attached forms a ring system selected from

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The compound according to any one of claims 1-42 or a pharmaceutically acceptable salt thereof, wherein
wherein the ring system is optionally substituted with 1 to 2 substituents R9;
R9 at each occurrence independently is halogen, —CN, C(═O)C1-6alkyl, C1-6alkyl, C1-6haloalkyl, C1-4alkoxy, C3-5cycloalkyl, or 5 to 6 membered heteroaryl.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The compound according to any one of claims 1-42 or a pharmaceutically acceptable salt thereof, wherein
wherein the ring system is optionally substituted with 1 to 2 substituents R9;
R9 at each occurrence independently is C1-6alkyl, C1-6haloalkyl, C1-4alkoxy, C3-5cycloalkyl, or 5 membered heteroaryl.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The compound according to any one of claims 1-42 or a pharmaceutically acceptable salt thereof, wherein
wherein the ring system is optionally substituted with 1 to 2 substituents R9;
R9 at each occurrence independently is Cl, —CN, acetyl, methyl, isopropyl, trifluoromethyl, methoxy, cyclopropyl, or 1,3-thiazolyl.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The compound according to any one of claims 1-42 or a pharmaceutically acceptable salt thereof, wherein
wherein the ring system is optionally substituted with 1 to 2 substituents R9;
R9 at each occurrence independently is methyl, isopropyl, trifluoromethyl, methoxy, cyclopropyl, or 1,3-thiazolyl.

### Claim 48 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is
(S)-3-((2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)amino)-N,5-dimethylhexanamide;
(3S)-3-((2-(8,8-difluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-methyl-5,6,7,8-tetrahydro-4-quinazolinyl)amino)-N,5-dimethylhexanamide;
(3S)—N,5-dimethyl-3-((7-methyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-quinazolinyl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((3-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-1-isoquinolinyl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)furo[3,2-d]pyrimidin-4-yl)amino)hexanamide;
(3S)—N,5-dimethyl-3-(((8R)-8-methyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)hexanamide;
(3S)-3-((6-acetyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)amino)-N,5-dimethylhexanamide;
(3S)—N,5-dimethyl-3-((2-methyl-5-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((5-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)[1,3]thiazolo[5,4-d]pyrimidin-7-yl)amino)hexanamide;
5,5-dimethyl-2-((2S)-4-methyl-2-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)pentyl)-3,5-dihydro-4H-imidazol-4-one;
(3S)—N,5-dimethyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)amino)hexanamide;
(3S)—N,5-dimethyl-3-(((8S)-8-methyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((7-methyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((9-methyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-9H-purin-6-yl)amino)hexanamide;
(3S)-3-((2-(8,8-difluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-quinazolinyl)amino)-N,5-dimethylhexanamide;
1-(6-(4-(((2S)-4-methyl-1-(4H-1,2,4-triazol-3-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
(3S)—N,5-dimethyl-3-((7-(2-propanyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-quinazolinyl)amino)hexanamide;
(3S)-3-(3-cyanophenyl)-N-methyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)propanamide;
1-(6-(4-(((2S)-4-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(4-(((2S)-1-(1H-imidazol-2-yl)-4-methyl-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
(3S)-3-((2-((7R)-7-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)-N,5-dimethylhexanamide;
(3S)—N,5-dimethyl-3-((7-methyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-quinazolinyl)amino)hexanamide;
(3S)-3-((7-cyano-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-quinazolinyl)amino)-N,5-dimethylhexanamide;
(3S)-3-((2-(8-fluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-quinazolinyl)amino)-N,5-dimethylhexanamide;
(3S)-3-((2-(8-fluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-methyl-5,6,7,8-tetrahydro-4-quinazolinyl)amino)-N,5-dimethylhexanamide;
(3S)-3-((7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)-N,5-dimethylhexanamide;
(3S)-3-((7-chloro-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-quinazolinyl)amino)-N,5-dimethylhexanamide;
(3S)—N,5-dimethyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-6H-pyrano[3,2-d]pyrimidin-4-yl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(trifluoromethyl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((6-methyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((7-methyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)pyrido[3,2-d]pyrimidin-4-yl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(trifluoromethyl)-4-quinazolinyl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(1,3-thiazol-2-yl)pyrido[3,2-d]pyrimidin-4-yl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)pyrido[3,2-d]pyrimidin-4-yl)amino)hexanamide;
(3S)-3-((7-cyclopropyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)pyrido[3,2-d]pyrimidin-4-yl)amino)-N,5-dimethylhexanamide;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
(3S)-3-((7-cyclopropyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-quinazolinyl)amino)-N,5-dimethylhexanamide;
(3S)—N,5-dimethyl-3-((6-methyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-quinazolinyl)amino)hexanamide;
(3S)-3-((7-methoxy-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)pyrido[3,2-d]pyrimidin-4-yl)amino)-N,5-dimethylhexanamide;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(1,3-thiazol-2-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(5-methyl-1,2,4-oxadiazol-3-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(1H-1,2,4-triazol-1-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(1H-pyrazol-1-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(1H-1,2,3-triazol-1-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(1,2-oxazol-3-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(3-methyl-1,2-oxazol-5-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
(3S)-3-((7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)-N-methyl-4-phenylbutanamide;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(5-methyl-1,3,4-thiadiazol-2-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(5-methyl-1,2-oxazol-3-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(4-(((2S)-1-(1H-imidazol-2-yl)-4-methyl-2-pentanyl)amino)-7,7-dimethyl-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(1H-1,2,3-triazol-4-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
(3S)—N,5-dimethyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)pyrido[3,4-d]pyrimidin-4-yl)amino)hexanamide;
1-(6-(4-(((2S)-4-methyl-1-(1,3-oxazol-2-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
(3S)—N,5-dimethyl-3-((7-methyl-2-(2-(2-(trifluoromethyl)-2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-quinazolinyl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(1,3-thiazol-2-yl)-4-quinazolinyl)amino)hexanamide; or
(S)-2-((2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)amino)-N,4-dimethylpentanamide.

### Claim 49 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is
(3S)-3-((2-(8,8-difluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-methyl-5,6,7,8-tetrahydro-4-quinazolinyl)amino)-N,5-dimethylhexanamide;
(3S)—N,5-dimethyl-3-((7-(2-propanyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-quinazolinyl)amino)hexanamide;
(3S)-3-((7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)-N,5-dimethylhexanamide;
(3S)—N,5-dimethyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(trifluoromethyl)-5,6,7,8-tetrahydro-4-quinazolinyl)amino)hexanamide;
(3S)—N,5-dimethyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(1,3-thiazol-2-yl)pyrido[3,2-d]pyrimidin-4-yl)amino)hexanamide;
(3S)-3-((7-cyclopropyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)pyrido[3,2-d]pyrimidin-4-yl)amino)-N,5-dimethylhexanamide;
(3S)-3-((7-cyclopropyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-quinazolinyl)amino)-N,5-dimethylhexanamide;
(3S)-3-((7-methoxy-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)pyrido[3,2-d]pyrimidin-4-yl)amino)-N,5-dimethylhexanamide;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(1,2-oxazol-3-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(3-methyl-1,2-oxazol-5-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(5-methyl-1,3,4-thiadiazol-2-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(5-methyl-1,2-oxazol-3-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(4-(((2S)-1-(1H-imidazol-2-yl)-4-methyl-2-pentanyl)amino)-7,7-dimethyl-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;
1-(6-(7,7-dimethyl-4-(((2S)-4-methyl-1-(1H-1,2,3-triazol-4-yl)-2-pentanyl)amino)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one; or
(3S)—N,5-dimethyl-3-((2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(1,3-thiazol-2-yl)-4-quinazolinyl)amino)hexanamide.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

A pharmaceutical composition comprising the compound according to any one of claims 1-49 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

A compound according to any one of claims 1-49, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 50 for use as a medicament.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

A compound according to any one of claims 1-49 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 50 for use in treating cancer.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

A compound according to any one of claims 1-49 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 50 for use in treating cancer, wherein one or more cells express KRAS G12C mutant protein.

### Claim 54 (depends on 52, 53)

The compound or pharmaceutical composition for use of claim 52 or 53, wherein the cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic/myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

Use of the compound according to any one of claims 1-49 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 50 in the preparation of a medicament for treating cancer.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

Use of the compound according to any one of claims 1-49 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 50 in the preparation of a medicament for treating cancer, wherein one or more cells express KRAS G12C mutant protein.

### Claim 57 (depends on 55, 56)

The use according to claim 55 or 56, wherein the cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic/myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to any one of to any one of claims 1-49 or a pharmaceutically acceptable salt thereof.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to any one of to any one of claims 1-49 or a pharmaceutically acceptable salt thereof, wherein one or more cells express KRAS G12C mutant protein.

### Claim 60 (depends on 58, 59)

The method according to claim 58 or 59, wherein the cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic/myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma.

### Claim 61 (depends on 58, 59)

The method according to claim 58 or 59, wherein the cancer is non-small cell lung cancer, colorectal cancer, pancreatic cancer, appendiceal cancer, endometrial cancer, esophageal cancer, cancer of unknown primary, ampullary cancer, gastric cancer, small bowel cancer, sinonasal cancer, bile duct cancer, or melanoma.

### Claim 62 (depends on 61)

The method according to claim 61, wherein the cancer is non-small cell lung cancer.

### Claim 63 (depends on 61)

The method according to claim 61, wherein the cancer is colorectal cancer.

### Claim 64 (depends on 61)

The method according to claim 61, wherein the cancer is pancreatic cancer.

### Claim 65 (depends on 58, 59, 60, 61, 62, 63, 64)

The method according to anyone of claims 58-64, wherein the subject has a cancer that was determined to have one or more cells expressing the KRAS G12C mutant protein prior to administration of the compound or a pharmaceutically acceptable salt thereof.

### Claim 66 (depends on 58, 59, 60, 61, 62, 63, 64, 65)

The method according to anyone of claims 58-65, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an Aurora kinase A inhibitor, AKT inhibitor, arginase inhibitor, CDK4/6 inhibitor, ErbB family inhibitor, ERK inhibitor, FAK inhibitor, FGFR inhibitor, glutaminase inhibitor, IGF-1R inhibitor, KIF18A inhibitor, MCL-1 inhibitor, MEK inhibitor, mTOR inhibitor, PD-1 inhibitor, PD-L1 inhibitor, PI3K inhibitor, Raf kinase inhibitor, SHP2 inhibitor, SOS1 inhibitor, Src kinase inhibitor, or one or more chemotherapeutic agent.
